Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Sponsor: Eastern Health
Terminated
Request of Health Canada after publication of https://doi.org/10.7326/M20-4207
Other terminated trials from Eastern Health
Other Corona Virus Infection trials with similar outcome
This PHASE3 trial investigates Corona Virus Infection and Coronavirus and is currently terminated or withdrawn. Eastern Health leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Terminated PHASE3
-
Nov 2024 — Jan 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — May 2022 [monthly]
Terminated PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE3
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Health
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- McMaster University
- University of Alberta
- University of British Columbia
- University of Manitoba
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .